Altimmune Announces Proposed Underwritten Public Offering of Securities
Altimmune, Inc., a late clinical-stage biopharmaceutical company focused on serious liver diseases, announced a proposed underwritten public offering of common stock and warrants. The net proceeds are intended to fund the upcoming Phase 3 trial of its lead candidate pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), as well as…